📍 SIBioC 2026 – Palacongressi Rimini
📅 September 30 – October 2, 2026
🔹 Booth 8
From September 30 to October 2, 2026, Sentinel Group will participate in the 58th SIBioC National Congress in Rimini, entitled “Awareness, Innovation and Sustainability: Building the Future of Laboratory Medicine”.
On this occasion, Sentinel Group will bring a clear message: diagnostics is not a single moment in the clinical journey, but a continuous process that supports patients through different and complementary stages, from prevention to monitoring. By integrating technologies, expertise and diagnostic solutions, laboratories can transform analytical data into meaningful insights that support timely, informed and personalized clinical decisions.
From prevention to monitoring: an integrated diagnostic pathway
The vision presented by Sentinel Group follows four interconnected stages: prevention, diagnostic assessment, specialized testing and monitoring. Each step plays a crucial role in identifying risk, supporting diagnosis and patient stratification, providing deeper clinical insights, and monitoring disease progression or therapeutic effectiveness over time.
Within this continuum, the laboratory becomes a key contributor, bridging analytical results with clinical decision-making and patient needs.
Three clinical areas at the core of the journey
The Group’s integrated approach focuses on three key areas of laboratory medicine: gastroenterology, with screening programs and intestinal biomarkers supporting prevention, inflammation assessment and gastrointestinal health; oncology, through tumor markers, metabolic profiling and solutions for therapeutic monitoring; and infectious diseases, with rapid testing solutions and applications for viral load monitoring, transplant patient management, and therapeutic drug monitoring of antibiotics and immunosuppressants.
In this framework, Sentinel Diagnostics contributes with solutions for clinical chemistry, molecular diagnostics and specialized monitoring. From colorectal cancer screening and intestinal biomarkers to molecular applications for transplant patient management and infectious disease testing, the portfolio is designed to deliver reliable, timely and clinically actionable results.
Eureka Lab Division expands the pathway with chromatography and mass spectrometry solutions dedicated to therapeutic drug monitoring (TDM), toxicology, metabolic profiling and specialized biomarkers.
PRIMA Lab complements the approach with rapid diagnostic tests designed for prevention and first-line assessment, helping to improve access to diagnostics and bring testing closer to patients.
Together, the three companies of the Group combine complementary expertise to support the patient’s journey, from risk identification through diagnosis and treatment monitoring to the assessment of therapeutic effectiveness.
Meet us in Rimini
Sentinel Group looks forward to welcoming you at Booth 8, Palacongressi Rimini, to discover the latest solutions from Sentinel Diagnostics, Eureka Lab Division and PRIMA Lab, and to engage with Laboratory Medicine professionals in a discussion on the evolution of integrated diagnostic pathways and their role in supporting clinical decision-making throughout the patient journey.